Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8–12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6–8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.
Citations
Citations to this article as recorded by
Characteristics of Newly Reported Chronic Hepatitis C Cases Among Adults in the United States, 2016–2023: Insights From Population‐Based Surveillance Shaoman Yin, Megan G. Hofmeister, Nicola D. Thompson, Eyasu H. Teshale Journal of Viral Hepatitis.2026;[Epub] CrossRef
Hepatitis C Virus (HCV) and Hepatitis D Virus (HDV): Divergent Pathways to Hepatocellular Carcinoma (HCC) and Therapeutic Strategies Abolfazl Jafarı-sales, Parniya Nouri-dizaj, Soheyla Hosseyni-nasababad, Sanam Karzar-torkambour, Mehrdad Pashazadeh, Aylin Golestani, Zahra Ghahremani, Sara Naebi Archives of Current Medical Research.2026; 7(1): 255. CrossRef
Acute Hepatitis C as an Acute Cause of Acute-on-chronic Liver Failure in Alcohol-associated Liver Disease Narendra S. Choudhary, Kunwar A. Singh, Swapnil Dhampalwar, Neeraj Saraf, Virendra Singh Journal of Clinical and Experimental Hepatology.2025; 15(1): 102423. CrossRef
Nanodiagnostics in global eradication of hepatitis C virus Mohammad Darvishi, Reza Amiri, Emad Ghannad, Samir Mehrabkhani, Nassim Rastgar, Mahkameh Razaghi, Jaya Bansal, Mamata Chahar, Pranchal Rajput, Hossein Saffarfar, Payam Ali-Khiavi, Ahmad Mobed, Yalda Yazdani Clinica Chimica Acta.2025; 565: 120013. CrossRef
Prevalence and drug resistance analysis of hepatitis C virus genotypes in Heilongjiang, China Bo Du, Le Yu, Kun Zhou, Han Qiao, Meng Wu, Dong Wang, Xi Jin, Jing Feng, Xingku Li, Rongzheng Zhang, Shuyun Zhang Infection, Genetics and Evolution.2025; 127: 105700. CrossRef
Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation Rebecca A Dieter, Aprajita Mattoo, Perry Hotchkis, Ian S Jaffe, Elaina P Weldon, Jonathan C Berger, Nicole M Ali, Robert A Montgomery, Bonnie E Lonze Nephrology Dialysis Transplantation.2025; 40(7): 1322. CrossRef
Southeast Asia burden and trend of Gastrointestinal tract cancers from 1990 to 2021 and its prediction to 2050: findings from the Global Burden of Disease Study 2021 Duanyu Wang, Minghao Tan, Pengkhun Nov International Journal of Colorectal Disease.2025;[Epub] CrossRef
Nanoparticle-based biosensor integrated with multiple cross-displacement amplification for visual and rapid identification of hepatitis B virus and hepatitis C virus Hang Zhang, Yuanfang Shi, Zengguang Wu, Qi Zhao, Yu Wang, Xinggui Yang, Yan Tan, Yi Wang, Zhenghua Xiao, Xu Chen, Anne Piantadosi Microbiology Spectrum.2025;[Epub] CrossRef
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer Lirui Tang, Haiying Que, Yuquan Wei, Ting Yang, Aiping Tong, Xiawei Wei Journal of Hematology & Oncology.2025;[Epub] CrossRef
Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities Lei Zhang, Ting Wang, Shan Zhou, Shengpeng Li, Ting Mo, Shuanghua Wu Frontiers in Public Health.2025;[Epub] CrossRef
Epidemiological features of viral hepatitis C in the Tomsk region Yu. A. Ermolaeva, I. R. Grishkevich, Yu. G. Samoilova Russian Journal of Infection and Immunity.2025; 15(2): 287. CrossRef
Macrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications Yongquan Chi, Haipeng Jiang, Yiyuan Yin, Xinyu Zhou, Yiyouyou Shao, Yongsheng Li, Jianhua Rao MedComm.2025;[Epub] CrossRef
Current treatments and the future of nanomedicine in hepatitis C Drue Julien, Horacio Bach Nanomedicine.2025; 20(13): 1589. CrossRef
Colorectal cancer screening to identify undiagnosed hepatitis C in an Austrian cohort Hannah Hofer, Sebastian Bachmayer, Hannah Oberthaler, Georg Semmler, Sarah Wernly, Sophie Gensluckner, Lea Maria Stangassinger, Bernhard Wernly, Ursula Huber-Schönauer, Bernhard Paulweber, Elmar Aigner, Gertie Janneke Oostingh, Christian Datz Central European Journal of Public Health.2025; 33(2): 83. CrossRef
Detection of anti-HCV antibodies in the clinical classification and epidemiological surveillance of HCV infection Robério Amorim de Almeida Pondé Molecular Biology Reports.2025;[Epub] CrossRef
Unmasking Cryoglobulinemia: A Cold‐Blooded Complication of Hepatitis C Alexandra M. Arges, Ari Levine, Ned Snyder Case Reports in Hepatology.2025;[Epub] CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang Virology Journal.2025;[Epub] CrossRef
Chronic hepatitis C mortality in Brazil from 2000 to 2019: An analysis of multiple causes of death Larissa Festa, Gerusa Maria Figueiredo, Fatima Mitiko Tengan Clinics.2025; 80: 100746. CrossRef
Shining light on liquid–liquid phase separation in chronic liver disease Ming-Hui Li, Yang Yang, Qi-Qi Dong, Wen-Jie Sun, Hui Tao, Jing-Jing Yang Drug Discovery Today.2025; 30(10): 104464. CrossRef
Increased rate of deceased donor liver transplantation for candidates willing to receive organs from donors with human immunodeficiency virus Zeba Nauroz, Sander Florman, Meenakshi M. Rana, Jennifer D. Motter, Jennifer C. Price, Sapna A. Mehta, Jonathan Hand, David Wojciechowski, Saima Aslam, Maricar Malinis, Nahel Elias, Ghady Haidar, Marcus R. Pereira, Jacques Simkins, Valentina Stosor, Cathe American Journal of Transplantation.2025;[Epub] CrossRef
Exploring nonstructural NS5B protein to design a multi-epitope-based vaccine against HCV: immuno-informatics approach Nouman Ali, Adeeba Ali, Muhammad Sheraz Yousuf, Arsheen Rehman, Saad Muhammad Islam, Bilal Ilyas, Aamir Ali In Silico Pharmacology.2025;[Epub] CrossRef
HCV Core Antigen Diagnostic Performance for Acute/Recent HCV Infection in People With HIV-1: A Systematic Review and Meta-Analysis Tsung-Yu Tsai, Guan-Jhou Chen, Hsin-Yun Sun, Chien-Ching Hung Open Forum Infectious Diseases.2025;[Epub] CrossRef
Rapid and simple detection of HCV RNA: enhanced colorimetric RT-LAMP method using unmodified gold nanoparticles Hanne Altın, Esra Agel, Ayse Istanbullu Tosun BMC Microbiology.2025;[Epub] CrossRef
Global burden of hepatitis C virus infection related to high body mass index and future forecast: an analysis based on the global burden of disease study 2021 Jiayi Chen, Shiyun Wu, Panpan Zhai, Xueting Ou, Liyang Zhou, Xingfei Pan Frontiers in Public Health.2025;[Epub] CrossRef
Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential Junju He, Hui Tan, Yanru Qiu, Yuchao Dan, Qian Wan, Lan Li, Jie Wu, Qibin Song, Hongbin Chen, Bin Xu Genes & Diseases.2025; : 101963. CrossRef
Epigenetic Mechanisms Involved in Hcv Infection and Human HCC Ximenya Glauce da Cunha Freire Lopes, Roque Ribeiro da Silva Júnior, Fernando Liberalino Fernandes, Laura Andrade Custódio de Oliveira, Vania Sousa Andrade, Fabiana Lima Bezerra, Josélio Maria Galvão de Araújo, Jenner Chrystian Veríssimo de Azevedo, Thale International Journal of Molecular Sciences.2025; 26(24): 12045. CrossRef
Global, regional, and National burden of hepatitis C from 1990 to 2021 and projections until 2030 Junzhu Bai, Hengliang Lv, Longhao Wang, Shumeng You, Dan Liu, Lilin Wang, Yuanyong Xu, Junfeng Lu, Wenyi Zhang BMC Infectious Diseases.2025;[Epub] CrossRef
HCV Genotype Distribution and Molecular Characteristics of HCV Core Domain I in Persons Living with HIV and HCV from Yunnan Province, China Yantao Zhu, Junyi Liu, Lijuan Kang, Fangchao Ruan, Jianjian Li, Nian Zhang, Yanling Chen, Zhiying Yao, Haihua Yang, Jun Leng, Jinglin Wang, Jiali Wang AIDS Research and Human Retroviruses.2025;[Epub] CrossRef
Hepatitis C: Evolving Epidemiology, Treatment Landscape, and Current Challenges Danwen Qiu, Magdalini Matziari The International Journal of Gastroenterology and Hepatology Diseases.2025;[Epub] CrossRef
Immune Responses to Anti-Hepatitis C Virus Antibodies during Pre-Liver Transplantation Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Recipients Associated with Post-Liver Transplantation Allograft Injury Shu-Hsien Lin, Kun-Ta Wu, Chih-Chi Wang, Kuang-Tzu Huang, Li-Wen Hsu, Hock-Liew Eng, King-Wah Chiu Antibodies.2024; 13(1): 7. CrossRef
Direct-Acting Antiviral Treatment for Acute Hepatitis C in Japanese Patients: Clinical Course and Outcomes Hiroshi Okano, Katsumi Mukai, Akira Nishimura Cureus.2024;[Epub] CrossRef
Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children Chaowapong Jarasvaraparn, Christopher Hartley, Wikrom Karnsakul Pathogens.2024; 13(2): 180. CrossRef
Improving HCV diagnosis following a false-negative anti-HCV result Xia Long, Yu Chen, Minggang Yin, Weiping Liu Clinical Chemistry and Laboratory Medicine (CCLM).2024; 62(10): e229. CrossRef
Toward hepatitis C virus elimination using artificial intelligence Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef
Una visión integral del manejo de la hepatitis C y el objetivo de erradicarla Juan Carlos Restrepo-Gutiérrez Hepatología.2024; 5(2): 120. CrossRef
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review Malik Sallam, Roaa Khalil Microorganisms.2024; 12(6): 1035. CrossRef
Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals Chen‐Hua Liu, Yu‐Ping Chang, Ji‐Yuh Lee, Chi‐Yi Chen, Wei‐Yu Kao, Chih‐Lin Lin, Sheng‐Shun Yang, Yu‐Lueng Shih, Cheng‐Yuan Peng, Fu‐Jen Lee, Ming‐Chang Tsai, Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao Journal of Medical Virology.2024;[Epub] CrossRef
Hepatitis C Virus (HCV) Infection: Pathogenesis, Oral Manifestations, and the Role of Direct-Acting Antiviral Therapy: A Narrative Review Dario Di Stasio, Agostino Guida, Antonio Romano, Massimo Petruzzi, Aldo Marrone, Fausto Fiori, Alberta Lucchese Journal of Clinical Medicine.2024; 13(14): 4012. CrossRef
An ultrasensitive fluorescence sensing platform for HCV detection based on the T7 isothermal amplification combined with aggregation-induced emission luminogens strategy Wuxiu Guo, Xin Zhu, Jinchao Li, Linhai Li Sensors and Actuators Reports.2024; 8: 100229. CrossRef
The Role of Epigenetic Mechanisms in the Pathogenesis of Hepatitis C Infection Justyna Żychowska, Maciej Ćmil, Patryk Skórka, Joanna Olejnik-Wojciechowska, Paulina Plewa, Estera Bakinowska, Kajetan Kiełbowski, Andrzej Pawlik Biomolecules.2024; 14(8): 986. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Acute Hepatitis C: Current Status and Future Perspectives Massimo Fasano, Francesco Ieva, Marianna Ciarallo, Bruno Caccianotti, Teresa Antonia Santantonio Viruses.2024; 16(11): 1739. CrossRef
Understanding Perceptions of Hepatitis C and Its Management Among People with Experience of Incarceration in Quebec, Canada: A Qualitative Study Guided by the Common Sense Self-Regulation Model Andrea Mambro, Sameh Mortazhejri, David Ortiz-Paredes, Andrea Patey, Guillaume Fontaine, Camille Dussault, Joseph Cox, Jeremy M. Grimshaw, Justin Presseau, Nadine Kronfli Viruses.2024; 16(12): 1910. CrossRef
Safety considerations in the management of hepatitis C and HIV co-infection Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Pablo Barreiro, Fernando de Jesus, Octavio Corral, Carmen de Mendoza Expert Opinion on Drug Safety.2023; 22(5): 363. CrossRef
Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari Arabian Journal of Chemistry.2023; 16(8): 105013. CrossRef
Oryza sativa L. Indica Seed Coat Ameliorated Concanavalin A—Induced Acute Hepatitis in Mice via MDM2/p53 and PKCα/MAPK1 Signaling Pathways Zhiye Zhao, Ye Li, Shancheng Guo, Yuxu Chen, Haiaolong Yin, Yaxian Li, Guiguang Cheng, Lei Tian International Journal of Molecular Sciences.2023; 24(19): 14503. CrossRef
Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C A. I. Gubenko, D. V. Goryachev, A. I. Muravieva, G. V. Shukshina Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation.2023; 13(4): 519. CrossRef
A Synopsis of Hepatitis C Virus Treatments and Future Perspectives Christian Medina, Alexis Hipólito García, Francis Isamarg Crespo, Félix Isidro Toro, Soriuska José Mayora, Juan Bautista De Sanctis Current Issues in Molecular Biology.2023; 45(10): 8255. CrossRef
First
Prev
